Codiak BioSciences, Inc. (CDAK) files for IPO.

IPO of Codiak BioSciences, Inc. will take place on October 13, 2020.  Codiak BioSciences is a clinical stage biopharmaceutical company, focused on the development of exosome-based therapies. The company uses its own engEx platform to create a deep pipeline of engineered exosomes to treat a wide range of diseases, including oncology, neoro-oncology, neuromuscular and infectious diseases.
 
The estimated value of the company after its IPO will be US$450 million. The IPO listed bookrunners are Goldman Sachs, Evercore ISI, William Blair and Wedbush PacGrow.